Comparator advice is "serious, explicit and non-ambiguous," warns German drug HTA body
This article was originally published in SRA
Germany's G-BA, the body in charge of the country's AMNOG early benefit assessments for new drugs, says that while its initial advice may be non-binding, it nevertheless expects pharmaceutical companies to "respect" its recommendations1.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.